Phase 3 trial reinforces favorability of roflumilast 0.05% cream for atopic dermatitis in children
Positive results from the pivotal phase 3 INTEGUMENT-PED study showed that children aged 2 to 5 years with atopic dermatitis who were treated with roflumilast 0.05% cream saw significant improvements as early as week 1. Image credit: | stock.adobe.com Roflumilast 0.05% cream is a steroid-free, once-a-day topical cream formulated to deliver the medication without disturbing … Read more